Paper36737488
Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
Zeng H and 6 others. Clin Exp Med, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Papers, record 36737488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36737488
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Sorafenib | |
| Bayes Theorem |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26910784 | A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. | Liver Int | 2016 | https://conductscience.org/library/papers/26910784 | PubMed |
| 2 | 29498924 | SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29498924 | PubMed |
| 3 | 34245592 | Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next? | Hepatology | 2021 | https://conductscience.org/library/papers/34245592 | PubMed |
| 4 | 26455499 | Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. | Eur J Nucl Med Mol Imaging | 2016 | https://conductscience.org/library/papers/26455499 | PubMed |
| 5 | 30791765 | Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. | Expert Rev Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30791765 | PubMed |
| 6 | 28648803 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. | Lancet Gastroenterol Hepatol | 2017 | https://conductscience.org/library/papers/28648803 | PubMed |
| 7 | 9862851 | Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. | Hepatology | 1999 | https://conductscience.org/library/papers/9862851 | PubMed |
| 8 | 28781171 | First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28781171 | PubMed |
| 9 | 32272656 | Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32272656 | PubMed |
| 10 | 31421157 | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. | J Hepatol | 2019 | https://conductscience.org/library/papers/31421157 | PubMed |
| 11 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 12 | 32782275 | Targeted therapy for hepatocellular carcinoma. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32782275 | PubMed |
| 13 | 24750853 | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. | Liver Int | 2015 | https://conductscience.org/library/papers/24750853 | PubMed |
| 14 | 17519900 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17519900 | PubMed |
| 15 | 19095497 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19095497 | PubMed |
| 16 | 34771591 | Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771591 | PubMed |
| 17 | 15050913 | Focus on hepatocellular carcinoma. | Cancer Cell | 2004 | https://conductscience.org/library/papers/15050913 | PubMed |
| 18 | 29107679 | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/29107679 | PubMed |
| 19 | 28687477 | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. | J Hepatol | 2017 | https://conductscience.org/library/papers/28687477 | PubMed |
| 20 | 27579537 | Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. | Oncotarget | 2016 | https://conductscience.org/library/papers/27579537 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42305858 | Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition. | J Hepatocell Carcinoma | 2025 | https://conductscience.org/library/papers/42305858 | PubMed |
| 40568833 | Sorafenib with or without co-interventions for hepatocellular carcinoma. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/40568833 | PubMed |
| 36986832 | Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36986832 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36737488
GET https://conductscience.org/api/papers/v1/36737488/references?page=2